MNPR

NASDAQ 已收盘

Monopar Therapeutics

70.29 USD
▼-0.46-0.65%
盘后 69.13 -1.65%
2026-11-19
市值
$467.60M
市盈率
—
EPS
-2.41
股息率
—
52 周区间
50.07 – 124.82
成交量
138.68K
Beta
1.61
目标价
127.85
52W 低 50.0752W 高 124.82
价格走势

公司简介

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging ...